Increasing the Quality and Efficiency of Clinical Trials
The mission of the Clinical Trials Transformation Initiative (CTTI) is to develop and drive the adoption of practices that will increase the quality and efficiency of clinical trials.
LRG Webcast Series: Updates on the Temozolomide Trial
Dr. Jason Sicklick of Moores Cancer Center at the University of California San Diego talks about the Phase II study of Temozolomide (TMZ) in advanced SDH-mutant/deficient GIST, a new study available to patients with SDH-deficient GIST.
Update on a New Clinical Trial Offered to Eligible GIST Patients
The INTRIGUE study is a Phase 3 clinical trial testing the investigational drug ripretinib (DCC-2618) for patients living with GIST that are no longer on imatinib due to progression or intolerance.
A Conversation with Breelyn Wilky, M.D.
Dr. Breelyn Wilky answering questions on a panel of GIST experts at Life Fest Miami, 2018. Colorado, Clinical Trials & Immunotherapy Dr. Wilky, Director of Sarcoma Translational Research at the University of [...]
The Magic of Clinical Trial Math
How to Make 2/3 = 1 (100%) In a recent discussion about the frequency of mutations in GIST, we noted that the most common mutation is KIT exon 11, which makes up about 2/3 [...]
Life Fest 2018: Pharma Panel: Apritinib Update for the GIST Patients & Caregivers
Pharma Panel: Overview of Promising Trials for GIST Blueprint Medicines View all life fest 2018 videos
Why Do Cancer Patients Join Clinical Trials?
At the most basic level, cancer patients join clinical trials because of perceived value and perceived cost. In this context, perceived cost refers to more than just financial cost, although that is important. Perceived [...]
Clinical Trials Offer Hope for GIST Patients
The Life Raft Group Clinic Trials Database currently lists 31 trials that are open that are or could be of interest to GIST patients. Many of the most interesting of these new drugs are [...]
In the beginning…Patient-reported outcomes
Patient-reported outcomes is a buzz-phase that we hear a lot these days. At the Life Raft Group, I was recently in a meeting where we were discussing patient-reported outcomes, the LRG registry and patient-powered [...]
Ignyta Announces Results for Potential New Cancer Treatment
Dr. Alexander Drilon of Memorial Sloan Kettering Cancer Center recently reported at AACR on a potential new cancer treatment, Entrectinib, a receptor tyrosine kinase (RTK) inhibitor developed to target tumors carrying NTRK1, NTRK2, NTRK3, [...]